NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hospital Moinhos de Vento
Conditions: Covid19
Interventions: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine, ChAdOx1 nCoV-19 Covid-19 Vaccine, Ad26.COV2.S COVID-19 Vaccine
Countries: Brazil
The present test-negative design study aims to estimate the real-world effectiveness of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 infection and its consequences following a mass vaccination campaign in the city of Toledo in Southern Brazil. Individuals aged 12 years or older who seek the public healthcare system with symptoms suggestive COVID-19 will be enrolled. Participants with a positive polymerase chain reaction (PCR) test for SARS-CoV-2 will be classified as cases, and those with negative PCR test for SARS-CoV-2 will be classified as controls. Cases will be followed-up for a period of one year by means of structured telephone interviews.
Sex: ALL
Age: 12 Years to —
Study type: OBSERVATIONAL
Inclusion Criteria: * Age ≥ 12 years old; * Resident of Toledo city; * Seeking care in the public healthcare system with symptoms suggestive of COVID-19 defined as follows: 1) ARI symptoms (nasal congestion, rhinorrhea, anosmia, sore throat, hoarseness, new or increased-from-baseline cough, sputum production, dyspnea, wheezing, myalgia) OR 2) Admitting diagnosis suggestive of ARI (pneumonia, upper respiratory infection, bronchitis, influenza, cough, asthma, viral respiratory illness, respiratory distress, AND/OR respiratory failure). * Nasal sample for SARS-CoV-2 diagnosis obtained as standard of care. Exclusion Criteria: * SARS-CoV-2-directed antiviral treatment within the past 30 days; * COVID-19 monoclonal antibody therapy within the past 90 days; * COVID-19 convalescent serum therapy within the past 90 days; * Lack of consent to participate.
- Toledo, Paraná, Brazil
- Toledo, Paraná, Brazil
- Toledo, Paraná, Brazil